Market Cap 826.40M
Revenue (ttm) 74.21M
Net Income (ttm) -521.96M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -703.36%
Debt to Equity Ratio 0.00
Volume 1,995,400
Avg Vol 1,703,504
Day's Range N/A - N/A
Shares Out 139.13M
Stochastic %K 82%
Beta 1.39
Analysts Strong Sell
Price Target $17.22

Company Profile

Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors.The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metap...

Industry: Biotechnology
Sector: Healthcare
Phone: 415 906 4324
Website: www.vir.bio
Address:
1800 Owens Street, Suite 900, San Francisco, United States
Electhim
Electhim Jan. 7 at 8:59 PM
$VIR you know what that is ? 2nd confirmation green candle. Setting up nicely could be surprise leading into JP conference
0 · Reply
Electhim
Electhim Jan. 7 at 8:00 PM
$VIR heading up. Approaching 200 ma
0 · Reply
Electhim
Electhim Jan. 7 at 7:57 PM
$VIR see the change Broke out of consolidation
0 · Reply
Electhim
Electhim Jan. 7 at 7:49 PM
$VIR anybody else notice we broke out of consolidation range today. We should see new highs and lows.
0 · Reply
Dunnieboy1
Dunnieboy1 Jan. 7 at 3:24 PM
$VIR we were promised a game changing year for Vir last year, perhaps it’s this year🙏, better late than never.
0 · Reply
mktfixer
mktfixer Jan. 7 at 2:28 AM
$VIR trading in a range until it's not...patience needed here MM is as devious as a snake...dropping it the other day to 5.55 made no sense, but that's the point...
1 · Reply
TDMF123
TDMF123 Jan. 6 at 3:50 PM
$VIR 3,726 $7.50 call contracts were just purchased with a January 16th expiration date. That’s two days after she speaks JP Morgan Conference 🤔🤔🤔
2 · Reply
Dunnieboy1
Dunnieboy1 Jan. 6 at 1:36 PM
$VIR In a report released today, Alec Stranahan from Bank of America Securities maintained a Buy rating on Vir Biotechnology, with a price target of $13.00.
2 · Reply
Dunnieboy1
Dunnieboy1 Jan. 6 at 8:48 AM
$VIR just pointing out Sato has sold 66,000 shares recently but still has a significant holding; NASDAQ:VIR - Get Free Report) Director Vicki Sato sold 22,000 shares of the stock in a transaction dated Friday, January 2nd. The stock was sold at an average price of $5.93, for a total transaction of $130,460.00. Following the sale, the director owned 1,166,391 shares of the company's stock, valued at $6,916,698.63.12
0 · Reply
McMillion1
McMillion1 Jan. 6 at 3:08 AM
0 · Reply
Latest News on VIR
Vir Biotechnology, Inc. (VIR) Q3 2025 Earnings Call Transcript

Nov 5, 2025, 9:41 PM EST - 2 months ago

Vir Biotechnology, Inc. (VIR) Q3 2025 Earnings Call Transcript


Vir Biotechnology, Inc. (VIR) Q2 2025 Earnings Call Transcript

Aug 6, 2025, 11:01 PM EDT - 5 months ago

Vir Biotechnology, Inc. (VIR) Q2 2025 Earnings Call Transcript


Vir Biotechnology: Hep B And Cancer Projects March On

Jul 23, 2025, 12:10 PM EDT - 6 months ago

Vir Biotechnology: Hep B And Cancer Projects March On


Vir Biotechnology, Inc. (VIR) Q1 2025 Earnings Call Transcript

May 7, 2025, 11:21 PM EDT - 8 months ago

Vir Biotechnology, Inc. (VIR) Q1 2025 Earnings Call Transcript


Vir Biotechnology, Inc. (VIR) Q4 2024 Earnings Call Transcript

Feb 26, 2025, 11:22 PM EST - 11 months ago

Vir Biotechnology, Inc. (VIR) Q4 2024 Earnings Call Transcript


Vir Biotechnology: A Rocket Off Phase 1 Data

Jan 9, 2025, 9:00 AM EST - 1 year ago

Vir Biotechnology: A Rocket Off Phase 1 Data


Electhim
Electhim Jan. 7 at 8:59 PM
$VIR you know what that is ? 2nd confirmation green candle. Setting up nicely could be surprise leading into JP conference
0 · Reply
Electhim
Electhim Jan. 7 at 8:00 PM
$VIR heading up. Approaching 200 ma
0 · Reply
Electhim
Electhim Jan. 7 at 7:57 PM
$VIR see the change Broke out of consolidation
0 · Reply
Electhim
Electhim Jan. 7 at 7:49 PM
$VIR anybody else notice we broke out of consolidation range today. We should see new highs and lows.
0 · Reply
Dunnieboy1
Dunnieboy1 Jan. 7 at 3:24 PM
$VIR we were promised a game changing year for Vir last year, perhaps it’s this year🙏, better late than never.
0 · Reply
mktfixer
mktfixer Jan. 7 at 2:28 AM
$VIR trading in a range until it's not...patience needed here MM is as devious as a snake...dropping it the other day to 5.55 made no sense, but that's the point...
1 · Reply
TDMF123
TDMF123 Jan. 6 at 3:50 PM
$VIR 3,726 $7.50 call contracts were just purchased with a January 16th expiration date. That’s two days after she speaks JP Morgan Conference 🤔🤔🤔
2 · Reply
Dunnieboy1
Dunnieboy1 Jan. 6 at 1:36 PM
$VIR In a report released today, Alec Stranahan from Bank of America Securities maintained a Buy rating on Vir Biotechnology, with a price target of $13.00.
2 · Reply
Dunnieboy1
Dunnieboy1 Jan. 6 at 8:48 AM
$VIR just pointing out Sato has sold 66,000 shares recently but still has a significant holding; NASDAQ:VIR - Get Free Report) Director Vicki Sato sold 22,000 shares of the stock in a transaction dated Friday, January 2nd. The stock was sold at an average price of $5.93, for a total transaction of $130,460.00. Following the sale, the director owned 1,166,391 shares of the company's stock, valued at $6,916,698.63.12
0 · Reply
McMillion1
McMillion1 Jan. 6 at 3:08 AM
0 · Reply
PCIntern
PCIntern Jan. 6 at 12:24 AM
$VIR this was the most ridiculous trading day here except for every other trading day. This better pay off or I’m gonna take the proverbial gas pipe.
0 · Reply
mktfixer
mktfixer Jan. 5 at 9:44 PM
$VIR throw us a bone before JP conference
0 · Reply
Dunnieboy1
Dunnieboy1 Jan. 5 at 9:08 PM
$VIR SAN FRANCISCO--(BUSINESS WIRE)-- Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14 at 3:45 p.m. PT in San Francisco, California. A live webcast of the presentation will be made available under Events & Presentations in the Investors section of the Vir Biotechnology website and will be archived for 30 days.
1 · Reply
metalcook
metalcook Jan. 5 at 8:12 PM
$VIR shorts almost all time high.
0 · Reply
Dunnieboy1
Dunnieboy1 Jan. 5 at 7:07 PM
$VIR Vicki Sato Chairman of Vir sold a further 22,000 shares, she was given 66,000 as part of her pre-ipo package in 2017, probably locked in till now, no big deal as she still has over 1m shares.
1 · Reply
Dunnieboy1
Dunnieboy1 Jan. 5 at 3:46 PM
$VIR big bashing today down 5/6% at one point, looks overdone & may recover by close of play.
0 · Reply
Electhim
Electhim Jan. 4 at 8:37 PM
$VIR A positive comprehensive Phase 1 readout for VIR-5500 in mCRPC — especially with stronger activity and clean safety — would very likely act as a near-term catalyst for VIR shares and could significantly improve investor perception of the PRO-XTEN oncology strategy. 
0 · Reply
Electhim
Electhim Jan. 4 at 8:24 PM
$VIR VIR-5500 is a dual-masked PSMA-targeting T-cell engager being developed in mCRPC. It is currently in Phase 1 dose-escalation as a monotherapy in heavily pre-treated patients, and the company has also dosed the first patients in a combination cohort with androgen-receptor pathway inhibitors (ARPIs).  • In their Q3 2025 corporate update, Vir explicitly noted that they plan to share a **comprehensive VIR-5500 data update in the first quarter of 2026 for the late-line (monotherapy) cohort. Stay Tuned. Long
0 · Reply
Dunnieboy1
Dunnieboy1 Jan. 2 at 11:24 PM
$VIR Viki Sato Chairman sold 44,000 shares for aprox $250,000, apparently she acquired 66,000 in the ipo in 2017.
1 · Reply
newTrader9999
newTrader9999 Dec. 31 at 12:47 PM
$VIR a horrible SP performance in 2025 ... does these overhyped CEOs accept a paycut in down years ...
0 · Reply
DelayDoctor
DelayDoctor Dec. 26 at 2:12 PM
$VIR Price action signals that reliability now matters more than headline momentum. Margin trajectory needs to confirm that scale creates leverage, not dilution. Risk compresses once delivery patterns become predictable. Stronger outcomes appear only when priorities stay focused.
1 · Reply
Dunnieboy1
Dunnieboy1 Dec. 25 at 12:23 AM
$VIR all the best to everyone👍
0 · Reply